Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stem Cell Therapy Needs More Than Just The Cells: Device Firms See Opening

This article was originally published in The Pink Sheet Daily

Executive Summary

Thermogenesis and Cytori Therapeutics are two firms that could benefit.

You may also be interested in...

Astellas Continues Regenerative Cell Therapy Funding, Signs With Cytori For Liver Disease

TOKYO - Sidetracking the human embryonic stem cell debate in the U.S., Astellas entered a strategic relationship with San Diego firm Cytori Therapeutics, a regenerative medicine company that relies mainly on adipose-derived - or fat-derived - stem cells from patients

Quality-Of-Life Data Favor Stenting Over Drugs In Short-Term

The high-profile COURAGE trial again raises the question of how soon stents should be placed in patients with coronary disease.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts